Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis

Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis

Stefan-Alexandru Artene,1 Adina Turcu-Stiolica,2 Richard Hartley,1 Marius Eugen Ciurea,3 Oana Daianu,1 Corina Brindusa,1 Oana Alexandru,4 Ligia Gabriela Tataranu,5 Stefana Oana Purcaru,1 Anica Dricu1 1Unit of Biochemistry, 2Department of Biostatistics, 3Department of Plastic and Reconstructive Surge...

Full description

Bibliographic Details
Main Authors: Artene S, Turcu-Stiolica A, Hartley R, Ciurea ME, Daianu O, Brindusa C, Alexandru O, Tataranu LG, Purcaru SO, Dricu A
Format: Article
Language:English
Published: Dove Medical Press 2016-11-01
Series:OncoTargets and Therapy
Subjects:
Malignant Glioma
Irinotecan
Bevacizumab
Dendritic Cell
Systematic Analysis
Online Access:https://www.dovepress.com/dendritic-cell-immunotherapy-versus-bevacizumab-plus-irinotecan-in-rec-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/dendritic-cell-immunotherapy-versus-bevacizumab-plus-irinotecan-in-rec-peer-reviewed-article-OTT

Similar Items